Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by AbCellera Biologics Inc.

< Previous 1 2 3 Next >
AbCellera to Report Second Quarter 2022 Financial Results on August 9, 2022
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
Lilly to Supply an Additional 150,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatment Options
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera Reports Q1 2022 Business Results
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera and Empirico Expand Strategic Multi-Target Antibody Discovery Collaboration
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference on May 2, 2022
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera to Report First Quarter 2022 Financial Results on May 10, 2022
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera Presents Data on T Cell Engager Platform at AACR 2022
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera Reports Full Year 2021 Business Results
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera to Participate Virtually in the Truist Securities AI Symposium – Biotech & Tools
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera-Discovered Antibody, Bebtelovimab, Receives U.S. FDA Emergency Use Authorization for the Treatment of Mild-to-Moderate COVID-19
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera to Present Virtually at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
Lilly to Supply up to 600,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatments
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera Announces Changes to Its Board of Directors
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera-Discovered Bamlanivimab Together with Etesevimab Authorized as the First and Only Antibody Therapy for Emergency Use in COVID-19 Patients Under the Age of 12
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera Announces the Appointment of Neil Aubuchon as Chief Commercial Officer
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera Reports Q3 2021 Business Results
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera Announces Virtual Presentations at Investor Conferences in November
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
Lilly to Supply 614,000 Additional Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab to the U.S. Government for the Treatment or Post-Exposure Prevention of COVID-19
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera to Report Third Quarter 2021 Financial Results on November 9, 2021
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
Lilly to Supply the EU and EEA with up to 220,000 Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
Emergency Use Authorization of AbCellera-Discovered Bamlanivimab Administered with Etesevimab Expanded by the FDA to Include Post-Exposure Prophylaxis for the Prevention of COVID-19
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera Acquires TetraGenetics, Enhancing Capabilities to Generate Antibodies Against High-Value Targets
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera Reports Q2 2021 Business Results
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
EQRx and AbCellera Announce Collaboration to Accelerate the Advancement of New Innovative Medicines
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera to Report Second Quarter 2021 Financial Results on August 12, 2021
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera Appoints Neil Berkley as Chief Business Officer
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera Continues Expansion and Strengthens Future Pandemic Preparedness with First-of- its-Kind GMP Manufacturing Facility for Therapeutic Antibodies in Canada
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera Announces Secondary Private Sale of 11.9 Million Common Shares
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.